Skip to main content
CNS & Neurological Disorders - Drug Targets aims to cover all the latest and outstanding developments on the medicinal chemistry, pharmacology, molecular biology, genomics and biochemistry of contemporary molecular targets involved in neurological and central nervous system (CNS) disorders e.g. disease specific proteins, receptors, enzymes, genes. Each issue of the journal will contain a series of timely in-depth reviews written by leaders in the field covering a range of current topics on drug targets involved in neurological and CNS disorders. As the discovery, identification, characterization and validation of novel human drug targets for neurological and CNS drug discovery continues to grow; this journal will be essential reading for all pharmaceutical scientists involved in drug discovery and development.

CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders) was previously published as Current Drug Targets-CNS & Neurological Disorders.

Publisher: Bentham Science Publishers

More about this publication?
Volume 6, Number 2, 2007

Articles

Favourites:
ADD

Metabotropic Glutamate Receptors in the Control of Mood Disorders
pp. 87-100(14)
Authors: Witkin, Jeffrey M.; Marek, Gerard J.; Johnson, Bryan G.; Schoepp, Darryle D.

Favourites:
ADD

The NMDA Receptor as a Therapeutic Target in Major Depressive Disorder
pp. 101-115(15)
Authors: Pittenger, Christopher; Sanacora, Gerard; Krystal, John H.

Favourites:
ADD

AMPA Receptors in the Therapeutic Management of Depression
pp. 117-126(10)
Authors: Bleakman, D.; Alt, A.; Witkin, J. M.

Favourites:
ADD
Favourites:
ADD

Triple Reuptake Inhibitors (“Broad Spectrum” Antidepressants)
pp. 141-149(9)
Authors: Skolnick, Phil; Basile, Anthony S.

Favourites:
ADD

Targeting Neurotrophic/Growth Factor Expression and Signaling for Antidepressant Drug Development
pp. 151-160(10)
Authors: Tanis, Keith Q.; Newton, Samuel S.; Duman, Ronald S.

Favourites:
ADD

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content